Instil Bio, Inc. (TIL)
NASDAQ:TIL
Want to see TIL full AI Analyst Report?
Top Page
Instil Bio
(NASDAQ:TIL)
Select Model
Select Model
Rating:44Neutral
Price Target:
$7.50
▼(-6.60% Downside)
Action:Reiterated
Date:06/12/26
The score is primarily weighed down by weak financial performance (no revenue, continued losses and negative free cash flow) despite improving burn, and bearish technicals with the stock trading below key moving averages. Valuation is constrained by negative earnings, while the recent governance-related corporate event is a mild offset.
Positive Factors
Improving cash burn
Operating cash burn has improved materially versus 2022–2023, reflecting tighter spending and better cost control. Sustained lower burn extends runway, reduces near-term funding pressure and dilution risk, and gives management more time to advance clinical programs over the next months.
Negative Factors
No revenue / clinical-stage profile
The absence of product revenue means the business model depends on successful clinical outcomes, partnerships or financings for value capture. Commercialization remains unproven, so long development timelines and binary clinical risks drive persistent funding and execution uncertainty.
Read all positive and negative factors
Positive Factors
Negative Factors
Improving cash burn
Operating cash burn has improved materially versus 2022–2023, reflecting tighter spending and better cost control. Sustained lower burn extends runway, reduces near-term funding pressure and dilution risk, and gives management more time to advance clinical programs over the next months.
Read all positive factors
Instil Bio (TIL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$53.78M
Dividend YieldN/A
Average Volume (3M)27.56K
Price to Earnings (P/E)―
Beta (1Y)4.92
Revenue GrowthN/A
EPS Growth40.85%
CountryUS
Employees14
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-7.08
Shares Outstanding6,781,976
10 Day Avg. Volume14,361
30 Day Avg. Volume27,558
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)0.64
Price to Sales (P/S)0.00
P/FCF Ratio-2.00
Enterprise Value/Market Cap0.92
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.07K
Enterprise Value/Ebitda-1.20
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.61
Revenue Forecast (FY)N/A
Instil Bio Business Overview & Revenue Model
Company Description
Instil Bio, Inc. operates as a clinical-stage biopharmaceutical firm, concentrating its efforts on devising novel therapeutic options for individuals battling cancer. A cornerstone of their research involves the advancement of autologous tumor-inf...
How the Company Makes Money
null...
Instil Bio Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
38
Negative
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -24.00K | -534.00K | 0.00 | 0.00 | -5.99M | 0.00 |
| EBITDA | -41.59M | -65.01M | -62.53M | -147.12M | -217.38M | -152.51M |
| Net Income | -47.38M | -71.37M | -74.14M | -156.09M | -223.18M | -156.79M |
Balance Sheet | ||||||
| Total Assets | 200.43M | 203.52M | 263.57M | 325.63M | 482.13M | 609.98M |
| Cash, Cash Equivalents and Short-Term Investments | 74.57M | 76.13M | 113.31M | 150.36M | 260.92M | 454.10M |
| Total Debt | 0.00 | 85.18M | 86.89M | 86.05M | 79.90M | 0.00 |
| Total Liabilities | 89.73M | 89.66M | 94.13M | 99.80M | 118.52M | 54.78M |
| Stockholders Equity | 110.70M | 113.87M | 169.44M | 225.83M | 363.61M | 555.20M |
Cash Flow | ||||||
| Free Cash Flow | -33.76M | -36.62M | -65.70M | -102.69M | -264.75M | -179.97M |
| Operating Cash Flow | -33.76M | -36.62M | -55.70M | -82.03M | -180.16M | -122.14M |
| Investing Cash Flow | 15.55M | 25.48M | 53.97M | 41.13M | 114.54M | -474.40M |
| Financing Cash Flow | 7.06M | 7.29M | 1.75M | 8.08M | 71.89M | 393.16M |
Instil Bio Technical Analysis
Negative
8.03
Price Trends
8.17
Negative
8.16
Negative
12.20
Negative
Market Momentum
-0.04
Positive
40.54
Neutral
8.77
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TIL, the sentiment is Negative. The current price of 8.03 is below the 20-day moving average (MA) of 8.08, below the 50-day MA of 8.17, and below the 200-day MA of 12.20, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 40.54 is Neutral, neither overbought nor oversold. The STOCH value of 8.77 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TIL.
Instil Bio Risk Analysis
Instil Bio disclosed 70 risk factors in its most recent earnings report. Instil Bio reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Instil Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $250.58M | -1.99 | -53.61% | ― | -100.00% | 44.78% | |
48 Neutral | $204.54M | -0.93 | -124.06% | ― | ― | 39.66% | |
45 Neutral | $197.47M | -2.05 | -30.90% | ― | ― | 10.70% | |
45 Neutral | $271.33M | -0.75 | 309.79% | ― | -35.61% | -68.92% | |
44 Neutral | $53.78M | -1.14 | -39.76% | ― | ― | 40.85% | |
43 Neutral | $60.38M | -0.97 | -91.94% | ― | 106.65% | 12.20% |
* Healthcare Sector Average
TIL
Instil Bio
7.93
-29.57
-78.85%
ZNTL
Zentalis Pharmaceuticals
3.52
2.06
141.10%
NKTX
Nkarta
2.76
0.85
44.50%
ALXO
ALX Oncology Holdings
1.52
0.98
181.48%
SRZN
Surrozen
23.37
13.97
148.62%
TCRX
TScan Therapeutics
0.92
-0.69
-42.67%
Instil Bio Corporate Events
Executive/Board ChangesShareholder Meetings
Instil Bio Shareholders Back Directors and Auditor at Meeting
Positive
Jun 11, 2026
Instil Bio, Inc. reported that on June 11, 2026 it held its 2026 Annual Meeting of Stockholders, at which approximately 84.9% of outstanding common shares were present or represented by proxy. Shareholders elected George Matcham and Neil Gibson as...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.